The combination of lung promoting and blood activating therapy with azithromycin in the treatment of pediatric bronchopneumonia
Objective Exploring the effect of lung promoting and blood activating therapy combined with azithromycin in the treatment of pediatric bronchopneumonia.Methods Retrospective analysis of the medical records of 102 children with bronchopneumonia in a hospital from October 2023 to January 2024.According to the treatment method,they were divided into a control group(treated with azithromycin)and an observation group(treated with lung promoting and blood activating method combined with azithromycin),with 51 cases in each group.The clinical efficacy,traditional Chinese medicine symptom score,cough situation[cough severity score(VAS),cough symptom score(CSS),simplified cough severity score(CET)],and adverse reactions were compared between the two groups.Results Compared of the two groups,the observation group had a higher total effective rate(P＜0.05);before treatment,there was no statistically significant difference(P＞0.05)in the comparison of TCM syndrome scores between groups;after treatment,both groups of TCM syndrome scores decreased,and the observation group had a lower score(P＜0.05);before treatment,there was no statistically significant difference in cough situation between the two groups of children(P＞0.05);after treatment,two groups of VAS,the CSS and CET scores decreased,and compared between groups,the observation group had lower scores(P＜0.05);there was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion For children with bronchopneumonia,the use of lung promoting and blood activating therapy combined with azithromycin has a better effect,can reduce TCM syndrome scores,improved symptoms of children,and with high safety.
BronchopneumoniaChildrenAzithromycinLung promoting and blood activating therapy
万方数据
维普
